TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03867279

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Flossing
Description: The reeducation exercises are: lunge and hold (the subject performs a lunge increasing the dorsiflexion of the ankle, advancing the tibia as much as possible without taking off the heel of the floor and without valgus of the knee, 15 repetition of 10 seconds of duration each); back squat (squat with a pike supported on scapulae); and chaturanga (from the prone position with extension of elbows and spine, the subject raises upper antero iliac spines performing a shoulder flexion and raising the pelvis to the ceiling maintaining the hip flexion and knees extended and keeping the heels touching the ground. The subjects included in this group will perform the exercises while a compression band is applied to the ankle.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Reeducation exercises
Description: The reeducation exercises are: lunge and hold (the subject performs a lunge increasing the dorsiflexion of the ankle, advancing the tibia as much as possible without taking off the heel of the floor and without valgus of the knee, 15 repetition of 10 seconds of duration each); back squat (squat with a pike supported on scapulae); and chaturanga (from the prone position with extension of elbows and spine, the subject raises upper antero iliac spines performing a shoulder flexion and raising the pelvis to the ceiling maintaining the hip flexion and knees extended and keeping the heels touching the ground.
Study: NCT04361825

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab 1500mg via IV administered for every 4weeks(fixed dosing for subjects \> 30 kg body weight) in Day 1 of each cycle and AZD 6738 240mg bid per os administered in each cycle days 1 and 7. One cycle is consisted of 28 days.
Study: NCT03189420

Intervention type: PROCEDURE
Intervention: Tumor resection
Description: The tumors will be resected in routine therapeutic surgeries

Intervention type: PROCEDURE
Intervention: Tumor resection
Description: The tumors will be resected in routine therapeutic surgeries
Study: NCT01570166

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HR
Description: HR was carried out under general anesthesia using a right subcostal incision with a midline extension. Intra-operative ultrasonography was performed routinely to evaluate the tumor burden, liver remnant, and the possibility of a negative resection margin. Anatomic resection, in the form of segmentectomy and/or subsegmentectomy as described by Makuuchi et al. (16) was the preferred surgical method of liver resection. Pringle's maneuver was routinely used with a clamp and unclamp time of 10 min and 5 min, respectively; this technique was used repeatedly throughout the entire procedure.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RFA
Description: For PRFA, we used a commercially available system with a 375-KHz computer-assisted radiofrequency generator (Elektrotom HiTT 106, Berchtold, Medizinelektronik, Germany) and an open-perfused electrode (Berchtold, Tuttlingen, Germany) of 15 cm (or 20 cm), 14 Ga, and a 15 mm (or 20 mm) active electrode tip with microbores.
Study: NCT01515878

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hemocontrol
Description: Blood Volume Tracking system using biofeedback
Study: NCT04344548

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic NK transfer
Description: Three doses of allogeneic NK cell transfer
Study: NCT04298515

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Nesfatin-1
Description: Blood will be taken from the patients on an empty stomach for measuring nesfatin-1 level

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Nesfatin-1
Description: Blood will be taken from the patients on an empty stomach for measuring nesfatin-1 level

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Nesfatin-1
Description: Blood will be taken from the patients on an empty stomach for measuring nesfatin-1 level
Study: NCT00865670

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin Monohydrate 600 mg Tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zithromax (azithromycin dihydrate) 600 mg Tablets
Study: NCT01332084

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HA wheat cereals
Description: HA wheat cereals used in SOTI test and as part of desensitization plan
Study: NCT03882190

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GnRHa
Description: patients in the experimental group are supposed to receive GnRHa preoperatively and postoperatively according to their individual situation
Study: NCT02158975

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN9708
Study: NCT01997853

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omega 3 fatty acid
Description: Patients with Chronic Periodontitis in Test Group were prescribed Omega 3 fatty acid tablets 300mg once daily for 12 weeks and SRP at baseline

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients with Chronic Periodontitis in Control Group were prescribed Placebo tablets once daily for 12 weeks and SRP
Study: NCT02840721

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06480605
Description: PF-06480605 500 mg IV Q2W x 7 Doses
Study: NCT00934479

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lubiprostone
Description: Following the initial stool and breath collections and because of differences in the FDA-approved dosing for the 2 subtypes of chronic constipation, (that is, chronic constipation (CC) versus constipation due to irritable bowel syndrome (C-IBS), the CC subjects received open-label lubiprostone 24 mcg orally twice daily for 4 weeks; while the C-IBS subjects received open-label lubiprostone 8 mcg orally twice daily for 4 weeks.
Study: NCT02096679

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9291
Description: Volunteer will receive a single oral dose of 20 mg \[14C\]-AZD9291 as a solution on Day 1
Study: NCT02866708

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intermittent negative pressure device
Description: This intervention study will be designed as a randomized cross-over study.
Study: NCT01758523

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dutasteride

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sugar pill
Study: NCT03148314

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vaginal misoprostol
Description: (800µgm.x 2 doses 3 hours).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: buccal/sublingual misoprostol
Description: 200 µgm.x4 hrs.x 6 doses
Study: NCT02583126

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guided Imagery and Music
Description: Modified and resource-oriented form of the Bonny Method of Guided Imagery and Music (BM-GIM)
Study: NCT03646825

Intervention type: DIETARY_SUPPLEMENT
Intervention: Natural Antioxidant supplement
Description: 1 capsule orally three times a day for 12 weeks
Study: NCT04330053

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental
Description: * Training will address issues such as: environmental security, identifying hazards that can lead to a fall, psychological support, getting up from a fall, standing techniques and calling for help.~* The exercise program will last for six months and will be based on the OTAGO exercise program, which includes five exercise groups: general warm-up, muscle strengthening exercises, balance exercises, range of motion and stretching exercises. The program will be performed individually or in groups of two people at most and will be conducted once a week in one of the 5 outpatient clinics under the supervision of a specialized OTAGO trainer, while seniors should repeat the exercises twice a week alone at home and also walk twice a week for at least half an hour.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: * Information / Education about falls The participants in this group will receive the same information - education as the participants of the 1st group.~* They will be given a leaflet with general gentle exercises (not fall prevention specific) for the home.
Study: NCT03504254

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI examination
Description: Three kinds of MRI techniques will be used in this study. These are (1) axial T1-weighted (T1WI) and T2-weighted imaging (T2WI), UTE MRI, (2) BOLD-based fMRI, and (3) diffusion tensor imaging (DTI).
Study: NCT01810861

Intervention type: OTHER
Intervention: There is no intervention in this study
Description: This is a non-interventional study.
Study: NCT00193258

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 10mg/kg IV infusion every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: 150 mg po daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib
Description: 400-600mg daily
Study: NCT04798521

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tele-HCV
Description: Patients will be prescribed HCV medication treatment for 4 weeks at a time. The study pharmacist will check in with the participant by telephone or telemedicine visit at week 0, week 4, and end of treatment to 1) determine general medication tolerance, 2) assess quality of adherence and 3) dispense medications. Peers will assist participants in keeping telehealth appointments and navigating medication pick up or storage. HCV labs will be repeated at 12 weeks post end of treatment and results will be relayed to the participant in the SVR12 follow up visit with the research assistant, along with follow up surveys. Those successfully achieving SVR12 will be counseled on ongoing harm reduction methods. Those showing persistent HCV viremia at 12 weeks post treatment will be referred to community-based HCV treatment providers for treatment re-initiation.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Community Linkage to Care
Description: Following study inclusion and enrollment, research staff will refer the participant to a local community health clinic to engage in hepatitis C care and seek treatment. Peers will assist patients to engage with local primary care and health plan resources and will receive an information sheet on optional clinics to attend and questions to ask their provider.
Study: NCT00761137

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3 mg tropicamide
Description: 3 mg tropicamide in intra-oral thin film

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3 mg tropicamide
Description: 3 mg tropicamide in intra-oral thin film

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3 mg tropicamide
Description: 3 mg tropicamide in intra-oral thin film

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0 mg tropicamide
Description: 0 mg tropicamide (placebo) in intra-oral thin film
Study: NCT02411227

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VR Driving
Description: Baseline: Tactical A3 scenario, composite score Post-Assessment: Tactical A4 scenario composite score
Study: NCT00761137

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0 mg tropicamide
Description: 0 mg tropicamide (placebo) in intra-oral thin film

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0 mg tropicamide
Description: 0 mg tropicamide (placebo) in intra-oral thin film

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0 mg tropicamide
Description: 0 mg tropicamide (placebo) in intra-oral thin film
Study: NCT04531514

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sensitivity to phonological rules & referents OR: Toddlers
Description: Assess whether the inclusion of a semantic reference decreases OR phonological rule learning

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sensitivity to phonological rules & referents FR: Toddlers
Description: Assess whether the inclusion of a semantic reference increases FR phonological rule learning
Study: NCT01751997

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Transplants from 8/8-matched Unrelated donors
Description: * Myeloablative conditioning~  1. Total body irradiation; 165 cGy, every 12 hours, 8 doses, days -7 to -4 (total 1320 cGy)~ 2. Cyclophosphamide; 60 mg/kg/day, IV for 30 minutes, days -3 to -2 (total 120 mg/kg)~ 3. Antithymocyte globulin (ATG); 1.25 mg/kg/day, IV for 6 hours, days -3 to -2, (total 2.5 mg/kg)~* Reduced-intensity conditioning; older patients (age \> 55 years) and/or patients with comorbidities~  1. Fludarabine; 30 mg/m\^2/day, IV for 1 hour, days -8 to -4 (total 150 mg/m\^2)~ 2. Busulfex; 3.2 mg/kg/day, IV for 3 hours, days -3 to -2 (total 6.4 mg/kg)~ 3. Total body irradiation; 200 cGy, every 12 hours 2 doses, days -1 (total 400 cGy)~ 4. ATG; 1.25 mg/kg/day, IV for 6 hours, days -3 to -2, (total 2.5 mg/kg)~* GVHD prophylaxis~  1. Tacrolimus; 0.03 mg/kg/day, IV for 24 hours from day -1 (0.12 mg/kg/day, PO, if tolerable)~ 2. Methotrexate; 5 mg/m\^2/day, IV push, days +1, +3, +6, +11

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transplants from family-mismatched/haploidentical donors
Description: * Reduced-intensity conditioning~  1. Total body irradiation; 200 cGy, every 12 hours, 4 doses, days -9 to -8 (total 800 cGy)~ 2. Fludarabine; 30 mg/m\^2/day, IV for 1 hour, days -7 to -3 (total 150 mg/m\^2)~ 3. Busulfex; 3.2 mg/kg/day, IV for 3 hours, days -6 to -5 (total 6.4 mg/kg)~ 4. ATG; 1.25 mg/kg/day, IV for 6 hours, days -4 to -1 (total 5.0 mg/kg)~* GVHD prophylaxis~  1. Tacrolimus; 0.03 mg/kg/day, IV for 24 hours from day -1 (0.12 mg/kg/day, PO, if tolerable)~ 2. Methotrexate; 5 mg/m\^2/day, IV push, days +1, +3, +6, +11
Study: NCT03210727

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Ready to CARE program
Description: The intervention is built upon a model of caregiver well-being that identifies four domains of quality of life: physical, psychological, social, and spiritual well-being. For each domain, there are stressors (i.e., factors that make it hard to be a caregiver) and buffers (i.e., factors that help people be effective caregivers). Our Ready to CARE intervention begins by presenting caregivers with the model in order to generate a profile of personal stressors and buffers. From there, caregivers select from a menu of strategies that can be used to minimize stressors and create buffers in their daily life. The investigators will have six 45-minute sessions with the caregivers that will primarily occur while the patient is admitted for stem cell reinfusion.
Study: NCT02191202

Intervention type: DRUG
Intervention: Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTI)
Study: NCT01087528

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PillCam™ (Capsule Endoscopy) Colon 2 capsule
Description: Medical Device
Study: NCT03955419

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: NO-NPO (Daesang WelLife Co., Ltd., Korea)
Description: 800 mL of carbohydrate beverage consists of 12.8% carbohydrates, 50 kcal/100 mL, 290 mOsm/kg.
Study: NCT01343654

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text messaging plus EMA
Description: Personalized, tailored text messaging to prompt medication adherence, with EMA random queries about nonadherence and drug use, and two-way messaging for participants to report critical events

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: usual care in one of the three participating ID clinics, along with usual care (if any) in the community for problematic drug and alcohol use
Study: NCT01126840

Intervention type: BEHAVIORAL
Intervention: Telephone Interview
Description: The phone interview should take 30-45 minutes to complete.

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Mailed questionnaire that contains questions about experiences living with colorectal cancer, take 45-60 minutes to complete.
Study: NCT02131740

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eye rubbing
Description: eye rubbing for 1 minute in horizontal direction clockwise, 5 second rest \& eye rubbing for a further 1 minute.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No eye rubbing
Description: This eye will not be rubbed
Study: NCT04357418

Intervention type: OTHER
Intervention: it is a survey
Description: this interview can be carried out face to face or remotely.

Intervention type: OTHER
Intervention: it is a survey
Description: this interview can be carried out face to face or remotely.
Study: NCT04506827

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Maxillary Sinus Augmentation
Description: Biomaterial Graft into the Maxillary Sinus
Study: NCT01201187

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YY-162
Description: YY-162(Ginkgo extract 30mg+Ginseng extract 50mg) 1T/twice a day(bid) for 8weeks, po medication

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 1T/twice a day(bid) for 8weeks, po medication
Study: NCT04506827

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Maxillary Sinus Augmentation
Description: Biomaterial Graft into the Maxillary Sinus

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Maxillary Sinus Augmentation
Description: Biomaterial Graft into the Maxillary Sinus

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Maxillary Sinus Graft with ABBM
Description: The maxillary sinuses in the control group are grafted with ABBM

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Maxillary Sinus Graft with TCP
Description: The maxillary sinuses in the test1 group are grafted with TCP

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Maxillary Sinus Graft with TCP + HA
Description: The maxillary sinuses in the test1 group are grafted with TCP + HA
Study: NCT02100748

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRV130
Description: TRV130 1 - 4 mg will be administered every 4 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRV130
Description: TRV130 1 - 4 mg will be administered every 4 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRV130
Description: TRV130 1 - 4 mg will be administered every 4 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRV130
Description: TRV130 1 - 4 mg will be administered every 4 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Morphine 4 mg will be administered every 4 hours

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered every 4 hours
Study: NCT00745485

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zoledronic acid
Study: NCT03636776

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality of life in metastatic BC
Description: 1 month after metastatic stage diagnosis, patients complete their 1st therapeutic sequence evaluation visit (T1) within the recommended standard time frames. If the disease remains stable or if a response to treatment is observed then patients continue their follow-up in the same therapeutic sequence (T1).~If progression occurs, treatment is modified and patients move on to the next therapeutic sequence (T2).~And so on as many times as necessary. Before each evaluation visit with investigator, patients complete the questionnaires QLQ-C30, BR23, STAI, BDI II
Study: NCT00398684

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single dose nevirapine to the mother and to the child
Description: One maternal 200 mg NVP dose at the onset of labor, and one dose of infant NVP (0.6 ml/6mg) between 48-72 hours after birth. \[Infants less than 2,500g received only 0.2mL/kg\]

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single dose nevirapine to the mother and placebo to the child
Description: One maternal 200 mg NVP dose at the onset of labor, and one dose of infant placebo (0.6 ml) between 48-72 hours after birth. \[Infants less than 2,500g received only 0.2mL/kg\]

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Single dose placebo to the mother and to the child
Description: One maternal placebo dose at the onset of labor, and one dose of infant placebo (0.6 ml) between 48-72 hours after birth. \[Infants less than 2,500g received only 0.2mL/kg\]
Study: NCT00898768

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Capsule endoscopy
Description: Capsule endoscopy at baseline and after 2 years
Study: NCT03230123

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Green banana biomass
Description: Green banana biomass will be suplemented to diet as 4.5 g per day.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Green banana biomass
Description: Green banana biomass will be suplemented to diet as 4.5 g per day.
Study: NCT00869440

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNS 7056
Description: Administered as a single intravenous injection by a syringe driver over 1 minute

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNS 7056
Description: Administered as a single intravenous injection by a syringe driver over 1 minute

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNS 7056
Description: Administered as a single intravenous injection by a syringe driver over 1 minute

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Administered as a single intravenous injection by a syringe driver over 1 minute
Study: NCT03304431

Intervention type: DRUG
Group type: OTHER
Intervention: Orotracheal Lidocaine Oral Spray application
Description: The induction of group L will be performed 5 minutes after administration of 10% topical lidocaine (Lidocaine pump spray 10% 50 ml) 160 mg (16 puffs) application
Study: NCT04629274

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: The patients will be asked to provide at least 2 peripheral blood samples of approximately 100 milliliters each time, with a minimum of 14 days interval between these 2 samples.If the results obtained with the 2 initial samples would be of interest to the Sponsor, the patient will be asked to come back for additional samplings with a maximum of 6 additional blood draws
Study: NCT01923311

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EVG
Description: Tablet (s) or tablet (s) for oral suspension (if unable to swallow) will be administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EVG
Description: Tablet (s) or tablet (s) for oral suspension (if unable to swallow) will be administered orally once daily
Study: NCT04009174

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Imaging Panel
Description: Initial Protocol (REB approval date 08-Sept-2011)~Pre-operative Imaging Panel~* \[18F\]-FCH PET + Dynamic CT~* MRI of the pelvis with endorectal coil (T1, T2, DW, DCE, MRS)~* 3D-Transrectal ultrasound~* Optional PET/MRI (added with Protocol Amend 1, REB approval date 22-Aug-2012)~* Optional Sodium (23Na) MRI (added with Protocol Amend 2, REB approval date 25-Feb-2013)~Protocol Amendment #3, REB approval date 20-Oct-2015:~Pre-operative Imaging Panel~* \[18-F\]-DCFPyL PET+Dynamic CT~* PET/MRI with endorectal coil~* 3D-Transrectal Ultrasound~* Optional Sodium (23Na) MRI
Study: NCT02405052

Intervention type: OTHER
Intervention: No intervention
Description: Validation of the Panic Screening Score